-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – FB-418 in Parkinson’s Disease
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - FB-418 in Parkinson's Disease report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. FB-418 in Parkinson's Disease Drug Details: FB-418 is under development for the...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – FB-825 in Allergic Asthma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - FB-825 in Allergic Asthma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. FB-825 in Allergic Asthma Drug Details: FB-825 is under development for the...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – FB-825 in Allergic Rhinitis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - FB-825 in Allergic Rhinitis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. FB-825 in Allergic Rhinitis Drug Details: FB-825 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – FB-418 in Amyotrophic Lateral Sclerosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - FB-418 in Amyotrophic Lateral Sclerosis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. FB-418 in Amyotrophic Lateral Sclerosis Drug Details: FB-418 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – FB-849 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - FB-849 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. FB-849 in Solid Tumor Drug Details: FB-849 is under development for...
-
Product Insights
NewNet Present Value Model: F. Hoffmann-La Roche Ltd’s IONIS-FB-LRx
Empower your strategies with our Net Present Value Model: F. Hoffmann-La Roche Ltd's IONIS-FB-LRx report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: Ionis Pharmaceuticals Inc’s IONIS-FB-LRx
Empower your strategies with our Net Present Value Model: Ionis Pharmaceuticals Inc's IONIS-FB-LRx report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Company Insights
Innovation and Patenting activity of FB Financial Corp Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of FB Financial Corp Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Iptacopan Hydrochloride in Membranoproliferative Glomerulonephritis (Mesangiocapillary Glomerulonephritis)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Iptacopan Hydrochloride in Membranoproliferative Glomerulonephritis (Mesangiocapillary Glomerulonephritis) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Iptacopan Hydrochloride in Membranoproliferative Glomerulonephritis (Mesangiocapillary Glomerulonephritis) Drug...